Multifaceted applications of bile salts in pharmacy: An emphasis on nanomedicine

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 3955-3971

  Elnaggar, Yosra S R ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Bile salt; Bilosomes; Liposomes; Nanomedicine; Size tunable nanoparticles

Indexed keywords

BILE SALT; BILOSOME; CHOLIC ACID; DRUG CARRIER; LIPOSOME; MACROGOL; NANOCARRIER; NANOPARTICLE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; UNCLASSIFIED DRUG; VACCINE; BILE ACID; MICELLE;

ABSORPTION; BIOCOMPATIBILITY; CANCER THERAPY; CHEMICAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; DRUG TARGETING; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; HYPERCHOLESTEROLEMIA; MICELLE; NANOENGINEERING; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; PHARMACY; PHYSICAL CHEMISTRY; REVIEW; SURFACE PROPERTY; CHEMICAL PHENOMENA; CHEMISTRY;

BILE ACIDS AND SALTS; CHEMICAL PHENOMENA; DRUG DELIVERY SYSTEMS; HUMANS; MICELLES; NANOMEDICINE; NANOPARTICLES;

EID: 84933545214     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S82558     Document Type: Review

References (100)

1. Enhsen A, Kramer W, Wess G. Bile acids in drug discovery. Drug Discov Today.1998;3(9):409–418.
2. Maldonado-Valderrama J, Wilde P, Macierzanka A, Mackie A. The role of bile salts in digestion. Adv Colloid Interface Sci. 2011;165(1): 36–46.
3. Li, G. Intestinal probiotics: interactions with bile salts and reduction of cholesterol. Procedia Environ Sci. 2012;12(Part B):1180–1186.
4. Conacher M, Alexander J, Brewer JM. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine. 2001;19(20–22): 2965–2974.
5. Fu ZD, Klaassen CD. Increased bile acids in enterohepatic circulation by short-term calorie restriction in male mice. Toxicol Appl Pharmacol. 2013;273(3):680–690.
6. Pols TWH, Noriega LG, Nomura M, Auwerx J, Schoonjans K. The bile acid membrane receptor TGR5 as an emerging target in metabolism and infammation. J Hepatol. 2011;54(6):1263–1272.
7. Madenci, D, Egelhaaf SU. Self-assembly in aqueous bile salt solutions. Curr Opin Colloid Interface Sci. 2010;15(1–2):109–115.
8. Baptissart M, Vega A, Maqdasy S, et al. Bile acids: from digestion to cancers. Biochimie. 2013;95(3):504–517.
9. Degirolamo C, Modica S, Palasciano G, Moschetta A. Bile acids and colon cancer: solving the puzzle with nuclear receptors. Trends Mol Med. 2011;17(10):564–572.
10. Morimoto K, Uehara Y, Iwanaga K, et al. Infuence of absorption enhancers (bile salts) and the preservative (benzalkonium chloride) on mucociliary function and permeation barrier function in rabbit tracheas. Eur J Pharm Sci. 1998;6(3):225–230.
11. Atanackovic M, Posa M, Heinle H, Gojković-Bukarica L, Cvejić J. Solubilization of resveratrol in micellar solutions of different bile acids. Colloids Surf B Biointerfaces. 2009;72(1):148–154.
12. Maestrelli F, Cirri M, Mennini N, Zerrouk N, Mura P. Improvement of oxaprozin solubility and permeability by the combined use of cyclo-dextrin, chitosan, and bile components. Eur J Pharm Biopharm. 2011; 78(3):385–393.
13. Selvam, S, Andrews ME, Mishra AK. A photophysical study on the role of bile salt hydrophobicity in solubilizing amphotericin B aggregates. J Pharm Sci. 2009;98(11):4153–4160.
14. Elnaggar YS, El-Refaie WM, El-Massik MA, Abdallah OY. Lecithin-based nanostructured gels for skin delivery: an update on state of art and recent applications. J Control Release. 2014;180: 10–24.
15. Romeo VD, deMeireles JC, Gries WJ, et al. Optimization of systemic nasal drug delivery with pharmaceutical excipients. Adv Drug Deliv Rev. 1998;29(1–2):117–133.
16. Shin S-C, Kim J-Y. Enhanced permeation of triamcinolone acetonide through the buccal mucosa. Eur J Pharm Biopharm. 2000;50(2): 217–220.
17. Shin S-C, Cho C-W, Yang K-H. Development of lidocaine gels for enhanced local anesthetic action. Int J Pharm. 2004;287(1–2): 73–78.
18. Bhat S, Maitra U. Low molecular mass cationic gelators derived from deoxycholic acid: remarkable gelation of aqueous solvents. Tetrahedron. 2007;63(31):7309–7320.
19. El-Refaieb WM, Elnagger YS, El-Massikb MA, Abdallaha OY. Novel self-assembled, gel-core hyaluosomes for non-invasive management of osteoarthritis: in-vitro optimization, ex-vivo and in-vivo permeation. Pharm Res. Epub March 17, 2015.
20. Elnaggar, YS, El-Massik MA, Abdallah OY. Fabrication, appraisal, and transdermal permeation of sildenafl citrate-loaded nanostructured lipid carriers versus solid lipid nanoparticles. Int J Nanomedicine. 2011; 6:3195–3205.
21. Elnaggar YS, El-Massik MA, Abdallah OY. Self-nanoemulsifying drug delivery systems of tamoxifen citrate: design and optimization. Int J Pharm. 2009;380(1–2):133–141.
22. Elsheikh MA, Elnaggar YS, Gohar EY, Abdallah OY. Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: optimization and in vivo appraisal. Int J Nanomedicine. 2012;7:3787–3802.
23. Freag MS, Elnaggar YS, Abdallah OY. Lyophilized phytosomal nano-carriers as platforms for enhanced diosmin delivery: optimization and ex vivo permeation. Int J Nanomedicine. 2013;8:2385–2397.
24. Freag MS, Elnaggar YS, Abdallah OY. Development of novel polymer-stabilized diosmin nanosuspensions: in vitro appraisal and ex vivo permeation. Int J Pharm. 2013;454(1):462–471.
25. Elnaggar YS, El-Massik MA, Abdallah O Y. Sildenafl citrate nano-emulsion vs self-nanoemulsifying delivery systems: rational development and transdermal permeation. Int J Nanotechnol. 2011;8(8): 749–763.
26. Harde H, Siddhapura K, Agrawal AK, Jain S. Development of dual toxoid-loaded layersomes for complete immunostimulatory response following peroral administration. Nanomedicine (Lond). 2015;10(7): 1077–1091.
27. Yingsukwattana K, Puttipipatkhachorn S, Ruktanonchai U, Sarisuta N. Enhanced permeability across Caco-2 cell monolayers by specific man-nosylating ligand of buserelin acetate proliposomes. J Liposome Res. Epub 2015;6:1–11.
28. Parmentier J, Becker MM, Heintz U, Fricker G. Stability of liposomes containing bio-enhancers and tetraether lipids in simulated gastrointestinal fuids. Int J Pharm. 2011;405(1–2):210–217.
29. Jain S, Harde H, Indulkar A, Agrawal AK. Improved stability and immunological potential of tetanus toxoid containing surface engineered bilosomes following oral administration. Nanomedicine. 2014; 10(2):431–440.
30. Gadras C, Santaella C, Vierling P. Improved stability of highly fuori-nated phospholipid-based vesicles in the presence of bile salts. J Control Release. 1999;57(1):29–34.
31. Hu S, Niu M, Hu F, et al. Integrity and stability of oral liposomes containing bile salts studied in simulated and ex vivo gastrointestinal media. Int J Pharm. 2013;441(1–2):693–700.
32. Andrieux K, Forte L, Lesieur S, Paternostre M, Ollivon M, Grabielle-Madelmont C. Solubilisation of dipalmitoylphosphatidylcholine bilay-ers by sodium taurocholate: a model to study the stability of liposomes in the gastrointestinal tract and their mechanism of interaction with a model bile salt. Eur J Pharm Biopharm. 2009;71(2):346–355.
33. Martin C, Thongborisute J, Takeuchi H, Yamamoto H, Kawashima Y, Alpar HO. Cholesterol–bile salt vesicles as potential delivery vehicles for drug and vaccine delivery. Int J Pharm. 2005;298(2):339–343.
34. Premanand B, Prabakaran M, Kiener TK, Kwang J. Recombinant baculovirus associated with bilosomes as an oral vaccine candidate against HEV71 infection in mice. PLoS One. 2013;8(2):e55536.
35. Senior K. Bilosomes: the answer to oral vaccine delivery? Drug Discov Today. 2001;6(20):1031–1032.
36. Shukla A, Katare OP, Singh B, Vyas SP. M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes. Int J Pharm. 2010;385(1–2):47–52.
37. Shukla A, Khatri K, Gupta PN, Goyal AK, Mehta A, Vyas SP. Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes). J Pharm Pharm Sci. 2008;11(1):59–66.
38. Shukla A, Singh B, Katare OP. Significant systemic and mucosal immune response induced on oral delivery of diphtheria toxoid using nano-bilosomes. Br J Pharmacol. 2011;164(2b):820–827.
39. Singh P, Prabakaran D, Jain S, Mishra V, Jaganathan KS, Vyas SP. Cholera toxin B subunit conjugated bile salt stabilized vesicles (bilo-somes) for oral immunization. Int J Pharm. 2004;278(2):379–390.
40. Niu M, Tan Y, Guan P, et al. Enhanced oral absorption of insulin-loaded liposomes containing bile salts: a mechanistic study. Int J Pharm. 2014; 460(1–2):119–130.
41. Chen Y, Lu Y, Chen J, et al. Enhanced bioavailability of the poorly water-soluble drug fenofbrate by using liposomes containing a bile salt. Int J Pharm. 2009;376(1–2):153–160.
42. Khatun Z, Nurunnabi M, Cho KJ, Lee YK. Imaging of the GI tract by QDs loaded heparin-deoxycholic acid (DOCA) nanoparticles. Carbo-hydr Polym. 2012;90(4):1461–1468.
43. Gao F, Li L, Zhang H, et al. Deoxycholic acid modified-carboxymethyl curdlan conjugate as a novel carrier of epirubicin: in vitro and in vivo studies. Int J Pharm. 2010;392(1–2):254–260.
44. Holm R, Mullertz A, Mu H. Bile salts and their importance for drug absorption. Int J Pharm. 2013;453(1):44–55.
45. Torcello-Gómez A, Maldonado-Valderrama J, De Vicente J, Cabrerizo-Vílchez MA, Gálvez-Ruiz MJ, Martín-Rodríguez A. Investigating the effect of surfactants on lipase interfacial behaviour in the presence of bile salts. Food Hydrocolloids. 2011;25(4):809–816.
46. Araya H, Nagao S, Tomita M, Hayashi M. The novel formulation design of self-emulsifying drug delivery systems (SEDDS) type O/W microemulsion I: enhancing effects on oral bioavailability of poorly water soluble compounds in rats and beagle dogs. Drug Metab Phar-macokinet. 2005;20(4):244–256.
47. Miyake K, Arima H, Irie T, Hirayama F, Uekama K. Enhanced absorption of cyclosporin A by complexation with dimethyl-beta-cyclodextrin in bile duct-cannulated and -noncannulated rats. Biol Pharm Bull. 1999; 22(1):66–72.
48. van Hasselt PM, Janssens GE, Slot TK, et al. The infuence of bile acids on the oral bioavailability of vitamin K encapsulated in polymeric micelles. J Control Release. 2009;133(2):161–168.
49. Kim EJ, Han KS, Lee MG. Enhanced absorption of oral furosemide by bile juice in rats. Res Commun Mol Pathol Pharmacol. 1999;104(1): 107–110.
50. Zhang Z, Gao F, Jiang S, et al. Bile salts enhance the intestinal absorption of lipophilic drug loaded lipid nanocarriers: mechanism and effect in rats. Int J Pharm. 2013;452(1–2):374–381.
51. Lofman M, Koivukorpi J, Noponen V, Salo H, Sievänen E. Bile acid alkylamide derivatives as low molecular weight organogelators: systematic gelation studies and qualitative structural analysis of the systems. J Colloid Interface Sci. 2011;360(2):633–644.
52. Patra D, Ahmadieh D, Aridi R. Study on interaction of bile salts with curcumin and curcumin embedded in dipalmitoyl-sn-glycero-3-phosphocholine liposome. Colloids Surf B Biointerfaces. 2013;110: 296–304.
53. Rupp C, Steckel H, Muller B W. Mixed micelle formation with phos-phatidylcholines: the infuence of surfactants with different molecule structures. Int J Pharm. 2010;387(1–2):120–128.
54. Gautrot JE, Zhu XX. Biodegradable polymers based on bile acids and potential biomedical applications. J Biomater Sci. 2006;17(10): 1123–1139.
55. Yang J, Gao C, Lü S, Zhang X, Yu C, Liu M. Physicochemical characterization of amphiphilic nanoparticles based on the novel starch-deoxycholic acid conjugates and self-aggregates. Carbohydr Polym. 2014;102:838–845.
56. Tang X, Cai S, Zhang R, et al. Paclitaxel-loaded nanoparticles of star-shaped cholic acid-core PLA-TPGS copolymer for breast cancer treatment. Nanoscale Res Lett. 2013;8(1):420.
57. Zeng X, Tao W, Mei L, Huang L, Tan C, Feng SS. Cholic acid-function-alized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer. Biomaterials. 2013;34(25): 6058–6067.
58. Li Y, Xiao K, Luo J, Lee J, Pan S, Lam KS. A novel size-tunable nanocarrier system for targeted anticancer drug delivery. J Control Release. 2010;144(3):314–323.
59. Gao F-P, Zhang, HZ, Liu, LR, et al. Preparation and physicochemi-cal characteristics of self-assembled nanoparticles of deoxycholic acid modified-carboxymethyl curdlan conjugates. Carbohydr Polym. 2008;71(4):606–613.
60. He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31(13):3657–3666.
61. Xiao K, Luo J, Fowler WL, et al. A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials. 2009;30(30): 6006–6016.
62. Luo J, Xiao K, Li Y, et al. Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment. Bioconjug Chem. 2010;21(7):1216–1224.
63. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9): 771–782.
64. Zahr AS, Davis CA, Pishko MV. Macrophage uptake of core-shell nanoparticles surface modified with poly(ethylene glycol). Langmuir. 2006;22(19):8178–8185.
65. Xiao K, Li Y, Luo J, et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials. 2011;32(13):3435–3446.
66. Ma N, Ma C, Li C, et al. Infuence of nanoparticle shape, size, and surface functionalization on cellular uptake. J Nanosci Nanotechnol. 2013;13(10): 6485–6498.
67. Lesniak A, Salvati A, Santos-Martinez MJ, Radomski MW, Dawson KA, Åberg C. Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency. J Am Chem Soc. 2013;135(4): 1438–1444.
68. Truong NP, Whittaker MR, Mak CW, Davis TP. The importance of nanoparticle shape in cancer drug delivery. Expert Opin Drug Deliv. 2015;12(1):129–142.
69. Mahajan S, Mahajan RK. Interactions of phenothiazine drugs with bile salts: micellization and binding studies. J Colloid Interface Sci. 2012;387(1):194–204.
70. Tan Y, Qi J, Lu Y, Hu F, Yin Z, Wu W. Lecithin in mixed micelles attenuates the cytotoxicity of bile salts in Caco-2 cells. Toxicol In Vitro. 2013;27(2): 714–720.
71. Israelachvili JN, Mitchell DJ, Ninham B W. Theory of self-assembly of lipid bilayers and vesicles. Biochim Biophys Acta. 1977;470(2): 185–201.
72. Yu JN, Zhu Y, Wang L, et al. Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate/phospholipid-mixed micelles. Acta Pharmacol Sin. 2010;31(6):759–764.
73. Wacker M, Schubert R. From mixed micelles to liposomes: critical steps during detergent removal by membrane dialysis. Int J Pharm. 1998;162(1–2):171–175.
74. Niu M, Lu Y, Hovgaard L, et al. Hypoglycemic activity and oral bio-availability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose. Eur J Pharm Biopharm. 2012;81(2):265–272.
75. Jain S, Indulkar A, Harde H, Agrawal AK. Oral mucosal immunization using glucomannosylated bilosomes. J Biomed Nanotechnol. 2014;10(6): 932–947.
76. Aburahma MH. Bile salts-containing vesicles: promising pharmaceutical carriers for oral delivery of poorly water-soluble drugs and peptide/protein-based therapeutics or vaccines. Drug Deliv. 2014: 1–21.
77. Yang L, Tucker IG, Ostergaard J. Effects of bile salts on propranolol distribution into liposomes studied by capillary electrophoresis. J Pharm Biomed Anal. 2011;56(3):553–559.
78. Guan P, Lu Y, Qi J, et al. Enhanced oral bioavailability of cyclo-sporine A by liposomes containing a bile salt. Int J Nanomedicine. 2011;6:965–974.
79. Elsheikh MA, Elnaggar YS, Abdallah OY. Rationale employment of cell culture versus conventional techniques in pharmaceutical appraisal of nanocarriers. J Control Release. 2014;194:92–102.
80. Heinen CA, Reuss S, Amidon GL, Langguth P. Ion pairing with bile salts modulates intestinal permeability and contributes to food-drug interaction of BCS class III compound trospium chloride. Mol Pharm. 2013;10(11): 3989–3996.
81. Song K-H, Chung S-J, Shim C-K. Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts. J Control Release. 2005;106(3):298–308.
82. Kokkona M, Kallinteri P, Fatouros D, Antimisiaris SG. Stability of SUV liposomes in the presence of cholate salts and pancreatic lipases: effect of lipid composition. Eur J Pharm Sci. 2000;9(3):245–252.
83. Kiselev MA, Janich M, Hildebrand A, Strunz P, Neubert RHH, Lombardo D. Structural transition in aqueous lipid/bile salt [DPPC/ NaDC] supramolecular aggregates: SANS and DLS study. Chem Phys. 2013;424:93–99.
84. Niu M, Lu Y, Hovgaard L, Wu W. Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation. Int J Nanomedicine. 2011;6:1155–1166.
85. Montanari J, Vera M, Mensi E, Morilla M, Romero E. Nanober-ries for topical delivery of antioxidants. J Cosmet Sci. 2013;64(6): 469–481.
86. Paolino D, Cosco D, Cilurzo F, et al. Improved in vitro and in vivo collagen biosynthesis by asiaticoside-loaded ultradeformable vesicles. J Control Release. 2012;162(1):143–151.
87. El Maghraby GM, Williams AC, Barry B W. Oestradiol skin delivery from ultradeformable liposomes: refinement of surfactant concentration. Int J Pharm. 2000;196(1):63–74.
88. Dai Y, Zhou R, Liu L, Lu Y, Qi J, Wu W. Liposomes containing bile salts as novel ocular delivery systems for tacrolimus (FK506): in vitro characterization and improved corneal permeation. Int J Nanomedicine. 2013;8:1921–1933.
89. Fu Q, Fu HL, Huan L, et al. Preparation of cefquinome sulfate proli-posome and its pharmacokinetics in rabbit. Iran J Pharm Res. 2013; 12(4):611–621.
90. Velpula A, Jukanti R, Janga KY, et al. Proliposome powders for enhanced intestinal absorption and bioavailability of raloxifene hydro-chloride: effect of surface charge. Drug Dev Ind Pharm. 2013;39(12): 1895–1906.
91. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun. 1991; 175(3):880–885.
92. Cuna M, Alonso-Sandel M, Remuñán-López C, Pivel JP, Alonso-Lebrero JL, Alonso MJ. Development of phosphorylated glucomannan-coated chitosan nanoparticles as nanocarriers for protein delivery. J Nanosci Nanotechnol. 2006;6(9–10):2887–2895.
93. Jain S, Vyas SP. Mannosylated niosomes as adjuvant-carrier system for oral mucosal immunization. J Liposome Res. 2006;16(4): 331–345.
94. Owen RL, Pierce NF, Apple RT, Cray WC Jr. M cell transport of Vibrio cholerae from the intestinal lumen into Peyer’s patches: a mechanism for antigen sampling and for microbial transepithelial migration. J Infect Dis. 1986;153(6):1108–1118.
95. Barnwell SG, Laudanski T, Dwyer M, et al. Reduced bioavailability of atenolol in man: the role of bile acids. Int J Pharm. 1993;89(3): 245–250.
96. Sasaki M, Maeda A, Sakamoto K, Fujimura A. Effect of bile acids on absorption of nitrendipine in healthy subjects. Br J Clin Pharmacol. 2001;52(6):699–701.
97. Amenitsch H, Edlund H, Khan A, Marques EF, La Mesa C. Bile salts form lyotropic liquid crystals. Colloids Surfaces A Physicochem Eng Aspects. 2003;213(1):79–92.
98. Paliwal R, Paliwal SR, Mishra N, Mehta A, Vyas SP. Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate. Int J Pharm. 2009;380(1–2):181–188.
99. Wilkhu JS, McNeil SE, Anderson DE, Perrie Y. Characterization and optimization of bilosomes for oral vaccine delivery. J Drug Target. 2013;21(3):291–299.
100. 100. Basha M, Abd El-Alim SH, Shamma RN, Awad GE. Design and optimization of surfactant-based nanovesicles for ocular delivery of Clotrimazole. J Liposome Res. 2013;23(3):203–210.